Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18592719 | 1.00 | CYP2D6 (0.35) | CYP2D6OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL18592713 | 1.00 | CYP2D6 (0.35) | CYP2D6OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL18592720 | 0.86 | — | — | |
| SCHEMBL4550439 | 0.86 | — | — | |
| SCHEMBL18592715 | 0.86 | — | — | |
| SCHEMBL22984864 | 0.85 | KDM4E (0.33) | CHRNA7HRH3 | |
| SCHEMBL10098670 | 0.85 | CYP2D6 (0.42) | CYP2D6OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2737187 | 0.79 | — | — | |
| SCHEMBL18471534 | 0.77 | CYP2D6 (0.37) | CYP2D6OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL18724550 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-09 | — | — | US | disclosed |
| US-20230250063-A1 | PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230250063-A1 | PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-10 | — | — | US | disclosed |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| US-20230013778-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LIMITED (IN) | 2023-01-19 | — | — | US | disclosed |
| WO-2022258622-A1 | COMBINATION TREATMENT OF CANCER | ARES TRADING S.A. (CH) | 2022-12-15 | — | — | WO | disclosed |
| WO-2011038163-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100152163-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009120717-A2 | PYRIDO [3, 4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| WO-2009055828-A1 | NEW TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | CYP2D6 1872/4885OPRM1 2621/4885OPRD1 2835/4885 |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | CYP2D6 3489/4885OPRM1 4599/4885OPRD1 4433/4885 |
| US-20230013778-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | SOS1, RSU1, KSR1 | CYP2D6 2174/4885OPRM1 511/4885OPRD1 1616/4885 |
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | CYP2D6 1629/4885OPRM1 3425/4885OPRD1 2892/4885 |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2D6 420/4885OPRM1 172/4885OPRD1 184/4885 |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | CYP2D6 4304/4885OPRM1 4702/4885OPRD1 4783/4885 |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | BRDT, BET1, BRD4 | CYP2D6 4337/4885OPRM1 4644/4885OPRD1 4198/4885 |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | CYP2D6 336/4885OPRM1 184/4885OPRD1 89/4885 |
| US-20100152163-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | HTR2C, HTR5A, HTR4 | CYP2D6 310/4885OPRM1 61/4885OPRD1 116/4885 |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | CYP2D6 4210/4885OPRM1 3593/4885OPRD1 4100/4885 |
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | KRAS, NRAS, HRAS | CYP2D6 2058/4885OPRM1 4566/4885OPRD1 4611/4885 |
| US-20230250063-A1 | PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | FPR2, FPR1, FPR3 | CYP2D6 2818/4885OPRM1 624/4885OPRD1 558/4885 |
| US-20090239854-A1 | Tetracyclic compounds | HTR2C, HTR3D, HTR5A | CYP2D6 1115/4885OPRM1 75/4885OPRD1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.